|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation:Effects on virus replication and recurrent hepatitis显示文摘瞄准:决定 calcineurin 禁止者, cyclosporine 和 tacrolimus 的效果,在丙肝上,在病人的周期性的丙肝的病毒(HCV ) 复制和活动张贴肝移植。方法:在我们的中心为在 1999 和 2003 之间的联系 HCV 的肝肝硬化收到了肝移植的 107 个病人的一个队的数据回顾地被分析。浆液 HCV-RNA 的水平和周期性的肝炎的活动在作为主要抑制免疫力的代理人和没在移植以后在开始的 12 瞬间以内导致胆汁的复杂并发症的不那样类似的抑制免疫力的政体收到了 cyclosporine 或 tacrolimus 的 47 个病人之间被比较。结果:HCV-RNA 在移植以后在 3 瞬间以内增加了,但是 cyclosporine 组和 tacrolimus 组之间的差别是不足道的(在 12 瞬间的 P=0.49 ) 。另外,由浆液 transaminases 决定了的周期性的肝炎并且门发炎和纤维变性的组织学的分级没在 12 瞬间(P=0.34 ) 以后显示出有效差量。结论:一个主要抑制免疫力的代理人不在肝移植以后在感染 HCV 的病人影响周期性的肝炎的正式就职或严厉的 Cyclosporine 或 tacrolimus。 | Philip Hilgard Alisan Kahraman Nils Lehmann Cornelia Seltmann Susanne Beckebaum R Stefan Ross Hideo A Baba Massimo Malago Christoph E Broelsch Guido Gerken | 2006 | World Journal of Gastroenterology2006，12，5： | 235 |
| 2 | Diagnosis of biliary strictures after liver transplantation:Which is the best tool?显示文摘AIM: To evaluate the diagnostic value of different indirect methods like biochemical parameters, ultrasound (US) analysis, CT-scan and MRI/MRCP in comparison with endoscopic retrograde cholangiography (ERC), for diagnosis of biliary complications after liver transplantation. METHODS: In 75 patients after liver transplantation, who received ERC due to suspected biliary complications, the result of the cholangiography was compared to the results of indirect imaging methods performed prior to ERC. The cholangiography showed no biliary stenosis (NoST) in 25 patients, AST in 27 and ITBL in 23 patients. RESULTS: Biliary congestion as a result of AST was detected with a sensitivity of 68.4% in US analysis (specificity 91%), of 71% in MRI (specificity 25%) and of 40% in CT (specificity 57.1%). In ITBL, biliary congestion was detected with a sensitivity of 58.8% in the US, 88.9%in MRI and of 83.3% in CT. However, as anastomotic or ischemic stenoses were the underlying cause of biliary congestion, the sensitivity of detection was very low. InMRI detected the dominant stenosis at a correct localization in 22% and CT in 10%, while US failed completely. The biochemical parameters, showed no significant difference in bilirubin (median 5.7; 4,1; 2.5 mg/dL), alkaline phosphatase (median 360; 339; 527 U/L) or gamma glutamyl transferase (median 277; 220; 239 U/L) levels between NoST, AST and ITBL.CONCLUSION: Our data confirm that indirect imaging methods to date cannot replace direct cholangiography for diagnosis of post transplant biliary stenoses. However MRI may have the potential to complement or precede imaging by cholangiography. Optimized MRCP-processing might further improve the diagnostic impact of this method. | Thomas Zoepf Evelyn J. Maldonado-Lopez Philip Hilgard Alexander Dech■ne Massimo Malago Christoph E. Broelsch Joerg Schlaak Guido Gerken | 2005 | World Journal of Gastroenterology2005，11，19： | 32 |
| 3 | Interferon-α response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment显示文摘AIM: To characterize the IFN-response and its modul- ation by the antiviral compound lamivudine in HBV- transfected HepG2.2.15 cells. METHODS: HepG2.2.15 and HepG2 cells were stimulated with various concentrations of IFN-a2a in the presence or absence of lamivudine. Then, total RNA was extracted and analysed by customised cDNA arrays and northern blot for interferon-inducible genes (ISGs). In addition, cellular proteins were extracted for EMSA and western blot. HBV replication was assessed by southern blot or ELISAs for HBsAg and HBeAg. RESULTS: Two genes (MxA, Cig5) with completely abolished and 4 genes (IFITM1, -2, -3, and 6-16) with partially reduced IFN-responses were identified in HepG2.2.15 cells. In 2 genes (IFITM1, 6-16), the response to IFN-a could be restored by treatment with lamivudine. This effect could not be explained by a direct modulation of the Jak/Stat signalling pathway since EMSA and western blot experiments revealed no suppression of Stat1 activation and ISGF3 formation after stimulation with IFN-a in HepG2.2.15 compared to HepG2 cells. CONCLUSION: These results are consistent with the assumption that chronic hepatitis B may specifically modulate the cellular response to IFN by a selective blockage of some ISGs. Antiviral treatment with lamivudine may partially restore ISG expression by reducing HBV gene expression and replication. | Shi-He Guan Mengji Lu Petra Grünewald Michael Roggendorf Guido Gerken Joerg F Schlaak | 2007 | World Journal of Gastroenterology2007，13，2： | 22 |
| 4 | Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients显示文摘AIM To investigate potential triggering factors leading to acute liver failure(ALF) as the initial presentation of autoimmune hepatitis(AIH).METHODS A total of 565 patients treated at our Department between 2005 and 2017 for histologically-proven AIH were retrospectively analyzed. However, 52 patients(9.2%) fulfilled the criteria for ALF defined by the 'American Association for the Study of the Liver(AASLD)'. According to this definition, patients with 'acute-on-chronic' or 'acute-on-cirrhosis' liver failure were excluded. Following parameters with focus on potential triggering factors were evaluated: Patients' demographics, causation of liver failure, laboratory data(liver enzymes, MELD-score, autoimmune markers, virus serology), liver histology, immunosuppressive regime, and finally, outcome of our patients.RESULTS The majority of patients with ALF were female(84.6%) and mean age was 43.6 ± 14.9 years. Interestingly, none of the patients with ALF was positive for antiliver kidney microsomal antibody(LKM). We could identify potential triggering factors in 26/52(50.0%) of previously healthy patients presenting ALF as their first manifestation of AIH. These were drug-induced ALF(57.7%), virus-induced ALF(30.8%), and preceding surgery in general anesthesia(11.5%), respectively. Unfortunately, 6 out of 52 patients(11.5%) did not survive ALF and 3 patients(5.7%) underwent liver transplantation(LT). Comparing data of survivors and patients with non-recovery following treatment, MELDscore(P < 0.001), age(P < 0.05), creatinine(P < 0.01), and finally, ALT-values(P < 0.05) reached statistical significance. CONCLUSION Drugs, viral infections, and previous surgery may trigger ALF as the initial presentation of AIH. Advanced age and high MELD-score were associated with lethal outcome. | Matthias Buechter Paul Manka Falko Markus Heinemann Monika Lindemann Hideo Andreas Baba Martin Schlattjan Ali Canbay Guido Gerken Alisan Kahraman | 2018 | World Journal of Gastroenterology2018，24，13： | 8 |
| 5 | Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro显示文摘瞄准:调查 cyclosporine 的效果 A (CsA )(MMF ) , FK-506,和 mycophenolate mofetil 和 40-0-[2-hydroxyethyl ] 人的肝内的增长上的 rapamycin (RAD ) 胆汁的上皮细胞(BEC ) 在试管内。方法:BEC 与免疫从六个人的肝织物标本被孤立磁性的分离方法并且与 CsA, FK-506, RAD,和 MMF 在试管内的不同集中对待。房间的增长被 MTT 试金分别地在 24 和 48 h 术后疗法测量。变化的单程的分析被用来分析结果。在 BEC 的 CK 19 的表示被流动血细胞计数和西方的污点监视。结果:BEC 的六根线被建立。他们为 4-18 wk 在试管内幸存。流动血细胞计数分析证明这些房间总是表示了 CK19。CsA, FK-506, RAD,和 MMF 以一种剂量依赖者方式禁止了 BEC 的增长。禁止 BEC (P<0.05 ) 的增长的 CsA, FK-506, RAD,和 MMF 的最低集中分别地是 500, 100, 0.25,和 100 mug/L。然而,由 BEC 的 CK19 的表示没被改变。结论:CsA, FK-506, RAD,和 MMF 在人的肝内 BEC 在试管内上有 antiproliferative 效果,当 RAD 有最强壮的生长禁止的效果时。他们在 transplant 病人的肝新生和胆汁管损害上的可能的效果应该进一步被调查。 | Chao Liu Thomas Schreiter Andrea Frilling Uta Dahmen Christoph E Broelsch Guido Gerken Ulrich Treichel | 2005 | World Journal of Gastroenterology2005，11，48： | 7 |
| 6 | Successful photodynamic therapy for biliary papillomatosis:A case report显示文摘Papillomatosis of the bile duct is a rare disease with a high risk of malignant transformation. Therapeutical options include partial hepatectomy and liver transplantation. A previously healthy 65-years old male developed jaundice and right upper abdominal quadrant pain in 1996. A villous adenoma of the distal bile duct was diagnosed. A Whipple procedure was performed. In 2002 the patient turned symptomatic again. Another adenoma was found in the right hepatic duct resulting in a right hepatectomy. Two years later the patient again developed cholestasis. After drainage of the left hepatic duct with a percutaneous transhepatic cholangial drainage (PTCD) catheter, a recurrent biliary adenomatosis was diagnosed by cholangioscopy. As there was no surgical option left, the patient received photodynamic therapy (PDT) for the recurrent biliary papillomatosis. Three mo after he received further photodynamic therapies, the bile duct epithelium appeared normal and the patient had no signs of adenomatosis, both macroscopically and histologically. The follow-up cholangioscopy in late 2005 revealed only a small papilloma without the need for intervention. In early 2006, the patient died of multi organ failure without signs of extrahepatic cholestasis or cholangitis at the age of 75, 10 years after the diagnosis of biliary papillomatosis was established. The patient exceeded the average life expectancy of patients with biliary papillomatosis by far. Thus, PDT might be a sufficient therapeutic option for recurrent papillomatosis patients with no significant side effects. | Lars P Bechmann Philip Hilgard Andrea Frilling Brigitte Schumacher Hideo A Baba Guido Gerken Thomas Zoepf | 2008 | World Journal of Gastroenterology2008，14，26： | 7 |
| 7 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial显示文摘 | Jordi Bruix Jean-Luc Raoul Morris Sherman Vincenzo Mazzaferro Luigi Bolondi Antonio Craxi Peter R. Galle Armando Santoro Michel Beaugrand Angelo Sangiovanni Camillo Porta Guido Gerken Jorge A. Marrero Andrea Nadel Michael Shan Marius Moscovici Dimitris Vo | 2012 | Journal of Hepatology2012，，4： | 6 |
| 8 | Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells显示文摘AIM To examine the influence on apoptotic mechanisms following inhibition of polo-like kinases as therapeuticallyapproach for cholangiocellular cancer treatment. METHODS As most cholangiocarcinomas are chemotherapyresistant due to mechanisms preventing tumor cell death, we investigated the effect of Cisplatin on cholangiocellular carcinoma(CCA) cell lines KMCH-1 and Mz-Ch-1. Polo-like kinases(PLK) are important regulators of the cell cycle and their inhibition is discussed as a potential therapy while PLK inhibition can regulate apoptotic mediators. Here, cells were treated with PLK inhibitor BI6727(Volasertib), Cisplatin, and in combination of both compounds. Cell viability was assessed by MTT; apoptosis was measured by DAPI staining and caspase-3/-7 assay. Western blot and q RT-PCR were used to measure expression levels of apoptosis-related molecules Bax and Bcl-2. RESULTS The cell viability in the CCA cell lines KMCH-1 and Mz-Ch-1 was reduced in all treatment conditions compared to vehicle-treated cells. Co-treatment with BI6727 and cisplatin could even enhance the cytotoxic effect of cisplatin single treatment. Thus, co-treatment of cisplatin with BI6727 could slightly enhance the cytotoxic effect of the cisplatin in both cell lines whereas there was evidence of increased apoptosis induction solely in Mz-Ch-1 as compared to KMCH-1. Moreover, PLK inhibition decreases protein levels of Bcl-2; an effect that can be reversed by the proteasomal degradation inhibitor MG-132. In contrast, protein levels of Bax were not found to be altered by PLK inhibition. These findings indicate that cytotoxic effects of Cisplatin in Mz-Ch-1 cells can be enhanced by co-treatment with BI6727.CONCLUSION In conclusion, BI6727 treatment can sensitize CCA cells to cisplatin-induced apoptosis with proteasomal Bcl-2 degradation as an additional pro-apoptotic effect. | Svenja Sydor Sami Jafoui Lena Wingerter Sandra Swoboda Joachim C Mertens Guido Gerken Ali Canbay Andreas Paul Christian D Fingas | 2017 | World Journal of Gastroenterology2017，23，22： | 5 |
| 9 | FibroSURE^(TM) and FibroScan~ in relation to treatment response in chronic hepatitis C virus显示文摘AIM:To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus(HCV)cohort.METHODS:Patients with chronic HCV were randomized to receive interferon-based therapy for 24(genotypes 2/3)or 48(genotype 1)wk.FibroSURE~TM(FS)was assessed at baseline and at week-12 post-treatment follow-up.Baseline biopsy for METAVIR was assessed by a single pathologist.FibroScan~ transient elastogra-phy(TE)was performed during treatment in a patient subset.RESULTS:Two thousand and sixty patients(n = 253 in Asia)were classif ied as METAVIR F0-1(n = 1682)or F2-4(n = 378).For F2-4,FS(n = 2055)had sensitiv-ity and specif icity of 0.87 and 0.61,respectively,with area under the receiver-operating curve of 0.82;corre-sponding values for TE(n = 214)and combined FS/TE(n = 209)were 0.77,0.88 and 0.88,and 0.93,0.68 and 0.88.Overall FS/TE agreement for F2-4 was 71%(κ = 0.41)and higher in Asians vs non-Asians(κ = 0.86 vs 0.35;P < 0.001).Combined FS/TE had 97% accuracy in Asians(n = 33).Baseline FS(0.38 vs 0.51,P < 0.001)and TE(8.0 kPa vs 11.9 kPa,P = 0.006)scores were lower in patients with sustained virological response than in nonresponders,and were maintained through follow-up.CONCLUSION:FS and TE may reliably differentiate mild from moderate-advanced disease,with a potential for high diagnostic accuracy in Asians with chronic HCV. | Keyur Patel Mireen Friedrich-Rust Yoav Lurie Mircea Grigorescu Carol Stanciu Chuan-Mo Lee Eugene R Schiff Dieter Hussinger Michael P Manns Guido Gerken Isabelle Colle Michael Torbenson Erik Pulkstenis G Mani Subramanian John G McHutchison Stefan Zeuzem | 2011 | World Journal of Gastroenterology2011，17，41： | 4 |
| 10 | Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival显示文摘 | Philip Hilgard Monia Hamami Amr El Fouly André Scherag Stefan Müller Judith Ertle Till Heusner Vito R. Cicinnati Andreas Paul Andreas Bockisch Guido Gerken Gerald Antoch | 2010 | Hepatology2010，，： | 3 |
| 11 | Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial显示文摘 | Harry LA Janssen Monika van Zonneveld Hakan Senturk Stefan Zeuzem Ulus S Akarca Yilmaz Cakaloglu Christopher Simon Thomas MK So Guido Gerken Robert A de Man Hubert GM Niesters Pieter Zondervan Bettina Hansen Solko W Schalm | 2005 | The Lancet . 2005 (9454)2005，，： | 2 |
| 12 | Endoscopic treatment of pediatric post‐transplant biliary complications is safe and effective显示文摘 | Alexander Dechêne Cathrin Kodde Simone Kathemann Jürgen Treckmann Elke Lainka Andreas Paul Guido Gerken Ariel E. Feldstein Peter F. Hoyer Ali Canbay | 2015 | Digestive Endoscopy2015，，4： | 2 |
| 13 | Right Living Donor Liver Transplantation: An Option for Adult Patients: Single Institution Experience With 74 Patients显示文摘 | Massimo Malagó Giuliano Testa Andrea Frilling Silvio Nadalin Camino Valentin-Gamazo Andreas Paul Hauke Lang Ulrich Treichel Vito Cicinnati Guido Gerken Christoph Erich Broelsch | 2003 | Annals of Surgery2003，，6： | 2 |
| 14 | DNA-based immunotherapy: potential for treatment of chronic viral hepatitis显示文摘 | Beckebaum S Cicinnati VR Gerken G | 2002 | Rev Med Virol2002，12，5： | 2 |
| 15 | Improved Detection of Inflammatory Bowel Disease by Additional Automated Motility Analysis in Magnetic Resonance Imaging显示文摘 | Maria L. Hahnemann Felix Nensa Sonja Kinner Stefan Maderwald Lale Umutlu Guido Gerken Thomas C. Lauenstein | 2015 | Investigative Radiology2015，，2： | 2 |
| 16 | Optimized endoscopic treatment of ischemic-type biliary lesions after liver transplantation显示文摘 | Thomas Zoepf Evelyn J. Maldonado de Dechêne Alexander Dechêne Massimo Malágo Susanne Beckebaum Andreas Paul Guido Gerken Philip Hilgard | 2012 | Gastrointestinal Endoscopy2012，，3： | 2 |
| 17 | Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis 显示文摘 | Weidemann C Gerken G | 1999 | J Hepatol1999，31，： | 1 |
| 18 | Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial显示文摘 | Harry LA Janssen Monika van Zonneveld Hakan Senturk Stefan Zeuzem Ulus S Akarca Yilmaz Cakaloglu Christopher Simon Thomas MK So Guido Gerken Robert A de Man Hubert GM Niesters Pieter Zondervan Bettina Hansen Solko W Schalm | 2005 | 2005 (9454)2005，，9454： | 1 |
| 19 | Turnover rate and kinetic mechanism for the reaction of hydrodechlorination of 1, 1-dichlorotertrafluoroethane(CF3-CFCl2) over a polycrystalling Pd foil显示文摘 | Riberio F H Gerken C A Somorjai G A | 1997 | Catal Lett1997，45，： | 1 |
| 20 | Clinical significance of autoantibodies to soluble liver aneigen in autoimmue hepatitis显示文摘 | Kanzler S Weidemann C Gerken G | 1999 | J Hepatol1999，31，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员